U.S. Markets open in 4 hrs 12 mins
  • S&P Futures

    3,783.50
    -6.00 (-0.16%)
     
  • Dow Futures

    30,720.00
    -61.00 (-0.20%)
     
  • Nasdaq Futures

    11,515.25
    -14.25 (-0.12%)
     
  • Russell 2000 Futures

    1,703.20
    -4.80 (-0.28%)
     
  • Crude Oil

    107.75
    +1.99 (+1.88%)
     
  • Gold

    1,795.10
    -12.20 (-0.68%)
     
  • Silver

    19.76
    -0.59 (-2.91%)
     
  • EUR/USD

    1.0458
    -0.0025 (-0.2405%)
     
  • 10-Yr Bond

    2.9720
    0.0000 (0.00%)
     
  • Vix

    28.84
    +0.68 (+2.41%)
     
  • GBP/USD

    1.2095
    -0.0080 (-0.6556%)
     
  • USD/JPY

    135.4400
    -0.2880 (-0.2122%)
     
  • BTC-USD

    19,491.11
    +381.82 (+2.00%)
     
  • CMC Crypto 200

    419.54
    -11.93 (-2.77%)
     
  • FTSE 100

    7,177.44
    +8.16 (+0.11%)
     
  • Nikkei 225

    25,935.62
    -457.42 (-1.73%)
     

Cyteir Therapeutics to Participate in the 2022 Bank of America Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

LEXINGTON, Mass., May 04, 2022--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that Andrew Gengos, Chief Business Officer and Judd Englert, MD, PhD, Senior Vice President Clinical Research & Development will participate in a fireside chat at the 2022 Bank of America Healthcare Conference. The meeting is being held in person in Las Vegas on Wednesday, May 11, 2022 at 4:20 p.m. ET (1:20 p.m. PT).

A live webcast of the presentation will be available in the Investors & Media section of the Cyteir website at www.cyteir.com. A webcast replay will also be available on the website shortly after conclusion of the event for 30 days.

About Cyteir Therapeutics, Inc.

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. At Cyteir, we employ an integrated target discovery approach that incorporates a critical evaluation of the target biology with internal and external information from a variety of genetic and chemical synthetic lethality screens to fuel our drug discovery and development pipeline. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors. Follow Cyteir on social media: LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005174/en/

Contacts

INVESTOR CONTACT:
Lisa Hayes
Vice President, Investor Relations and Corporate Communications
908-868-8926
Lisa.Hayes@cyteir.com

MEDIA CONTACT:
Michele Parisi
925-429-1850
mparisi@forwardhealthinc.com